tirzepatide approved for weight loss Eli Lilly drug data released Compounded Tirzepatide (GLP-1/GIP)

approval in 2025 for cardiovascular risk reduction in high-risk adults with type 2 diabetes, while the approval of the Wegovy pill in December 2025 marked the entry of oral GLP-1 therapy into the mainstream obesity market

Wed love to meet you, contact us today to schedule an appointment and take the first step towards a more comfortable and healthier life!

In this article, well investigate into the insights from Mayo Clinic, exploring the common and less common side effects of Tirzepatide, as well as those that may require immediate medical attention

Research has shown that GLP-1 receptor agonists can help reduce liver fat and inflammation